August 24, 2026
When MedTech executives talk about the talent crisis in Europe, the conversation almost always lands on the same roles: Regulatory Affairs specialists, Clinical Affairs managers, Quality Systems leaders navigating the MDR/IVDR backlog. These are real and well-documented shortages. But there is a second talent crisis developing below the surface — quieter, less discussed, and in some respects more structurally damaging.
It is happening inside manufacturing, engineering, and supply chain functions. And the pressure driving it is not the regulatory complexity that dominates industry headlines. It is something broader: the wholesale restructuring of how European MedTech companies build, source, and move product.
Three pressures have converged to push European MedTech manufacturers into a supply chain rethink — and they are happening simultaneously, not sequentially.
In the years following COVID-19, the vulnerabilities of globally distributed, single-source supply chains became painfully visible. Medical device manufacturers discovered dependencies on Chinese raw materials and sub-tier suppliers they had not fully mapped. That exposure did not resolve when the pandemic ended; it sharpened, as trade policy became more volatile. US tariffs on European medical device exports — effective April 2025 at a 20% increase — changed the competitive equation for manufacturers selling into the American market, prompting a structural rethink of production footprints and sourcing strategy across Europe.
Senior leaders in the sector are responding accordingly. Scenario planning has become central to executive decision-making, with companies systematically evaluating which parts of their supply chains are exposed to geopolitical risk and what resilience genuinely looks like — beyond the theoretical. Diversification of supplier bases, nearshoring of critical components, and the rebuilding of sub-tier visibility are no longer aspirational; they are active programmes with headcount requirements attached.
The EU's regulatory overhaul has added significant new obligations for manufacturers that extend well beyond market access. EUDAMED — the European database on medical devices — moved into mandatory registration phase on May 28, 2026, requiring manufacturers to register all device models with unique device identifiers before market placement, upload notified body certificates, and maintain ongoing data accuracy. This is not a one-time compliance exercise; it is a permanent operational function.
The European Commission's December 2025 amendments to the MDR and IVDR introduced standardised timelines for notified body processes (30 days for application review, 120 days for QMS audits, 90 days for product verification), which create new internal coordination demands for manufacturers managing multiple submissions in parallel. As these obligations scale, so does the demand for quality engineers and supplier quality professionals who can manage the operational substance behind them — not just the documentation.
Even before the reshuffling began, European MedTech manufacturing was operating in a constrained talent environment. Of the 28,512 MDR certification applications lodged through late 2025, only 10,554 certificates had been issued — a 37% certification rate, with average review times of 13 to 18 months for successful certifications. The professionals needed to prepare and manage those submissions — and to hold supply chains together while devices remain in limbo — were already overcommitted. The new wave of nearshoring and supplier diversification programmes is landing on top of that pre-existing strain.
The roles under acute pressure are operational and deeply technical. They include supplier quality engineers and leaders with documented experience in medical device environments; process, automation, and validation engineers who can translate new manufacturing setups into compliant processes; and supply chain risk and resilience specialists who understand both the commercial realities and the regulatory requirements of sourcing in a regulated industry.
Strategic sourcing professionals with fluency in tariff structures and geopolitical trade dynamics are in particularly short supply. Those who combine that expertise with medical device supply chain experience are commanding salary premiums of 15 to 25% above standard market rates — a reflection of how few candidates exist and how high the demand has become.
The core challenge: These are not roles where candidates from adjacent industries can simply be brought across. Manufacturing engineers in automotive or aerospace do not automatically qualify for medical device work without significant regulatory retraining. The same applies to supply chain professionals from food or consumer goods. The EU's regulated manufacturing environment requires specific knowledge — of quality management systems aligned to ISO 13485, of process validation requirements, of supplier qualification under MDR obligations — that takes time to acquire and cannot be shortcut.
The shortage extends into engineering more broadly. Demand for regulatory-grade systems engineers — those who can bridge technical design with compliance requirements — far outstrips supply across UK and EU markets. Universities produce competent engineers, but few graduates arrive with the regulatory literacy that medical device work demands. At the same time, experienced professionals are retiring faster than early-career talent can be developed to replace them. Large multinationals are absorbing the limited specialist pool available; smaller manufacturers and scale-ups are left competing for candidates who are not there.
Regulatory and clinical hiring in European MedTech has received sustained attention over the past three years, rightly so. The market for Regulatory Affairs Directors, Clinical Operations Managers, and Quality Assurance specialists has been visibly competitive, with role tenure shortening and counter-offer activity rising. That conversation has prompted investment in employer branding, compensation benchmarking, and talent pipeline development in those functions.
The same conversation has not yet happened for manufacturing engineering and supply chain leadership. These functions have historically been treated as mature, stable parts of the hiring market — steady demand, reasonable supply, manageable salaries. That assumption no longer holds. The structural changes underway in European MedTech manufacturing mean that demand for operational talent is accelerating precisely when supply is constrained and the gap between what candidates know and what companies need is widening.
Europe does possess some of the world's strongest scientific and engineering talent ecosystems. Universities, research institutions, and healthcare infrastructure create a genuine competitive advantage. But realising that advantage in a period of supply chain restructuring requires more deliberate investment in building and retaining operational capability than most manufacturers are currently making.
For companies in the middle of supply chain restructuring programmes, the talent implications need to be planned alongside the operational ones — not treated as a downstream problem to solve once the strategy is set.
Supplier diversification and nearshoring create immediate demand for supplier qualification engineers and sourcing specialists who can set up new relationships under the regulatory requirements of the EU MDR. Process transfers and new manufacturing site activations require validation engineers and process development resources. Supply chain risk monitoring — increasingly being digitised through predictive analytics and digital twin technologies — requires professionals who can operate these tools within a regulated quality management environment.
Each of these headcount requirements has a lead time. Specialist candidates take months to recruit in a competitive market, and onboarding into a regulated manufacturing environment takes longer still. Companies that treat these roles as positions to open when the need becomes urgent will find themselves behind — and the cost of delay in a supply chain transition is measured in disrupted production, delayed certifications, and regulatory exposure.
The manufacturers navigating this period most effectively are those building talent acquisition strategies for operational and engineering functions with the same rigour they apply to regulatory and clinical hiring. That means understanding the candidate market before roles open, building relationships with specialist recruiters who know the engineering and supply chain talent pool in their geography, and making competitive offers that reflect how scarce this expertise has become.
Europe's MedTech supply chain is undergoing a structural shift that will take years to complete. The regulatory environment, geopolitical pressures, and post-COVID resilience strategies driving that shift are not temporary conditions — they represent a new baseline that manufacturers are being asked to build operational capability around.
The talent required to build that capability is in short supply and growing shorter. Manufacturing engineers, supplier quality specialists, process validation professionals, and supply chain leaders with regulated industry experience are becoming as strategically important — and as difficult to hire — as the regulatory and clinical functions that have dominated the conversation until now.
The companies that recognise this early and invest in their operational talent pipeline accordingly will have a structural advantage that extends well beyond the current period of disruption.
We place manufacturing engineers, supplier quality leaders, and supply chain specialists across Europe's medical device sector. If your organisation is navigating supply chain restructuring and needs operational talent that understands the regulatory environment, we should speak.
Contact 44 International to discuss your hiring requirements.
© All rights reserved